These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18346407)

  • 1. Onycholysis associated with capecitabine in patients with breast cancer.
    Hogeling M; Howard J; Kanigsberg N; Finkelstein H
    J Cutan Med Surg; 2008; 12(2):93-5. PubMed ID: 18346407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Onycholysis with the appearance of a "sunset" secondary to capecitabine.
    Maino KL; Norwood C; Stashower ME
    Cutis; 2003 Sep; 72(3):234-6. PubMed ID: 14533836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Capecitabine-induced hyperpigmentation].
    Vázquez-Bayo C; Rodríguez-Bujaldón AL; Jiménez-Puya R; Galán-Gutiérrez M; Moreno-Giménez JC
    Actas Dermosifiliogr; 2007 Sep; 98(7):491-3. PubMed ID: 17669305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onychomadesis and onycholysis associated with capecitabine.
    Chen GY; Chen YH; Hsu MM; Tsao CJ; Chen WC
    Br J Dermatol; 2001 Sep; 145(3):521-2. PubMed ID: 11531857
    [No Abstract]   [Full Text] [Related]  

  • 5. Granulomatous septal panniculitis associated with capecitabine (Xeloda).
    Dalmau J; Roé E; Puig L; Alomar A
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):121-2. PubMed ID: 18181993
    [No Abstract]   [Full Text] [Related]  

  • 6. [Onycholysis with hyponychium exudate secondary to chemotherapy with paclitaxel and capecitabine].
    Tejera A; Bosch RJ; López N; Herrera E
    Actas Dermosifiliogr; 2006 Oct; 97(8):536-8. PubMed ID: 17067535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal melanonychia induced by capecitabine.
    Paravar T; Hymes SR
    Dermatol Online J; 2009 Oct; 15(10):11. PubMed ID: 19951629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.
    Bar-Sela G; Haim N
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):779-82. PubMed ID: 18641989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of capecitabine-induced hyperpigmentation and radiation recall phenomenon.
    Ghosal N; Misra V
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):632. PubMed ID: 19304468
    [No Abstract]   [Full Text] [Related]  

  • 10. Capecitabine induced inflammation of actinic keratoses.
    Krathen M; Treat J; James WD
    Dermatol Online J; 2007 Oct; 13(4):13. PubMed ID: 18319010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A woman with palmar and plantar hyperpigmentation].
    van Tienhoven G; Wilmink JW
    Ned Tijdschr Geneeskd; 2011; 155(45):A4100. PubMed ID: 22085578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Severe capecitabine-associated toxicity in a patient carrying a mutation in the dihydropyrimidine dehydrogenase gen].
    González-Haba E
    Farm Hosp; 2012; 36(6):554-5. PubMed ID: 23461455
    [No Abstract]   [Full Text] [Related]  

  • 13. [Efficiency of the capecitabine in patients with breast cancer with liver metastasis].
    Gasanzade DA; Zeĭnalov RS; Musaev IN
    Georgian Med News; 2009; (172-173):13-6. PubMed ID: 19644181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute coronary syndrome induced by capecitabine therapy.
    Wijesinghe N; Thompson PI; McAlister H
    Heart Lung Circ; 2006 Oct; 15(5):337-9. PubMed ID: 16697705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine induced colitis.
    Maggo G; Grover SC; Grin A
    Pathol Res Pract; 2014 Sep; 210(9):606-8. PubMed ID: 24947412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer.
    Bell KA; Perna AG; Hsu S
    J Am Acad Dermatol; 2001 Nov; 45(5):790-1. PubMed ID: 11606938
    [No Abstract]   [Full Text] [Related]  

  • 17. Coronary spasm induced by capecitabine.
    Schnetzler B; Popova N; Collao Lamb C; Sappino AP
    Ann Oncol; 2001 May; 12(5):723-4. PubMed ID: 11432636
    [No Abstract]   [Full Text] [Related]  

  • 18. Nursing considerations for capecitabine-based combination therapy.
    Becze E
    ONS Connect; 2009 Apr; 24(4):14-5. PubMed ID: 19413236
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
    Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
    Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects.
    Stathopoulos GP; Koutantos J; Lazaki H; Rigatos SK; Stathopoulos J; Deliconstantinos G
    Anticancer Res; 2007; 27(3B):1653-6. PubMed ID: 17595791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.